Vendor Intelligence Report: Shanghai Leader Peptide Biotechnology

Published 12 Jun 2026. 24-page investigative report on who is behind Shanghai Leader Peptide Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Shanghai Leader Peptide Biotechnology is not a blanket vendor call; it is a product-specific risk case. Across 50 Finnrick lab tests the vendor recorded 34 pass / 13 fail, an overall pass rate of 68%. GHK-Cu and tirzepatide are the relatively stronger signals, while tesamorelin is the weak point and retatrutide remains mixed enough that lot-level verification matters. Under stricter Finnrick grading, the record becomes less forgiving.

The public business trail is younger than the website biography. The site presents a 2017 establishment, staged expansion, and a 2023-style longevity signal; independent domain, archive, and WordPress asset records cluster around late 2025. Open Chinese registry searches did not verify the named entity, and the claimed Shanghai manufacturing footprint is not substantiated by the address context captured in the report.

The channel trail adds buyer-recourse risk. Researchers captured UK WhatsApp numbers, a Telegram handle tied by profile-image matching to a UK LinkedIn identity, and an Instagram account promoting the same GLP-1 line; this supports a visible Western-facing sales operator, not proven ownership. The site had WooCommerce installed but no working checkout, and a separate content-farm review reframed adverse testing language as a quality badge.

Inside the full report:

  • Appendix A with full Finnrick lab data and methodology-divergence charts for all 4 tested peptides
  • Dated evidence timeline comparing history claims with domain, archive, and WordPress asset records
  • Homepage, Gentaur, Telegram, Instagram, and LinkedIn exhibits mapping the customer-facing channel
  • Shanghai address and facility-claim analysis, including multi-tenant building context
  • Ordering-flow and buyer-recourse review covering the missing checkout and private-message sales path
  • Search-reputation scan, X/referral negatives, and FDA/CBP import-enforcement context

Risk assessment

  • Misleading corporate history and registry uncertainty — high: 2017/2023 history claims are unsupported by the Oct. 16, 2025 domain record, no pre-2025 Wayback history, and no verified open-registry match for the Chinese name.
  • Unverified manufacturing facility claims — high: The claimed 7F Jiading address and multi-tenant context do not substantiate large-scale synthesis, HPLC purification, lyophilization, and analytical-lab claims.
  • Operator and channel transparency risk — high: Sales are routed through Telegram/WhatsApp, a UK-facing Benedict Summers profile, and multiple inconsistent contact numbers without an authoritative channel list.
  • Payment and transaction-recourse risk — high: Checkout and shop pages were non-functional; message-based ordering and reported Bitcoin workflows leave buyers with little practical recourse.
  • Tesamorelin quality-control risk — high: Tesamorelin is the weakest tested product: 46.31% Finnrick rating with 4 pass / 4 fail, materially worse than the vendor's own GHK-Cu and tirzepatide records.
  • Retatrutide reliability risk — medium: Retatrutide is mixed rather than clean: 70.49% Finnrick rating across 22 tests, with 15 pass / 7 fail.
  • Search-reputation manipulation risk — medium: A content-farm review page used fake-author presentation and deceptive rating language; attribution to the vendor is not proven.
  • Regulatory and import-seizure risk — medium: Leader markets GLP-1-class peptides in an active FDA/CBP enforcement environment, although the vendor is not named in the cited actions.